Impact of a smartphone application on skin self-examination rates in patients who are new to total body photography: A randomized controlled trial
To the Editor: A number of studies support an association between higher skin self-examination (SSE) rates and thinner, more treatable, melanomas at diagnosis, [1] [2] [3] highlighting the importance of skin examinations. Despite this, rates of SSE by adults are as low as 7% in the general population and 10% in high-risk groups. 4, 5 One such high-risk group is patients who warrant professional total body photography (TBP). With TBP, the patient receives 20 to 50 photographs produced with professional lighting and a contrasting background to optimize image quality. The patient uses these photographs to compare against when checking for new or changing pigmented skin lesions. Patients, however, report potential barriers to using their printed photographs, such as inefficient organization, privacy concerns, and an inability to magnify. Consequently, we investigated whether adding the use of a smartphone application (app) loaded with a patient's TBP photographs could help lower these barriers and improve SSE rates compared with when patients received only printed photographs and a compact disc (CD) of digital versions.
Between February 2015 and October 2016, patients were randomized to receive either (1) the usual care at the University of Pennsylvania, consisting of printed photographs and a CD of digital photographs, or (2) the intervention consisting of digital photographs loaded onto an iPhone or iPad in addition to prints and the CD. The primary outcome variable was the change in SSE rates as assessed by enrollment and end-of-study surveys.
The mean age of the participants was 47.3 years (standard deviation, 14.9) in the intervention group and 47.5 (standard deviation, 15.1) in the usual care group; 100% of the study population was white, and 42% had graduate or professional training (Table I ). The average time between when the patient started in the study to when they completed the end-of-study survey was 218 days (7.25 months). Table II shows that SSE rates increased significantly over the study period (odds ratio, 3.39; 95% confidence interval, 1.14-10.09) with no difference between the study arms (P ¼ .55). Overall, 20% of our study population, regardless of study arm, performed regular skin examinations at baseline, with the rate increasing 6 months later to 37%. In addition, overall satisfaction was significantly higher in the intervention group than in the usual care group, with satisfaction rates of 94% and 54%, respectively (P \.001). Ease of use, ability to identify new or changing skin lesions, photograph organization, and privacy were all rated significantly higher in the intervention group. Importantly, these differences are observed in a population that volunteered to participate in a study using a mobile app, and consequently, they may not generalize to all patients.
In this study, we demonstrated that the usual care consisting of TBP prints and a CD of digital versions is an effective method of increasing skin examination rates, and that the addition of a mobile app is just as effective but associated with improved satisfaction, which may lead to improved skin self-examination compliance rates. These results, along with the knowledge that a subset of patients preferred the mobile app, help establish mobile technology as a viable alternative for patients to use and for clinicians to offer in support of regular skin self-examinations. Boldface indicates statistical significance. TBP, Total body photography; app, application; CD, compact disc; OR, odds ratio. *Odds ratio describing change in SSE rates within the intervention and usual care groups (study arm is held constant and is not an explanatory variable in the statistical model). y Odds ratio describing change in SSE rates with study arm as an explanatory variable in the statistical model. z Visit describes the effect of either the intervention or usual care when the study arm is held constant. With study arm as an explanatory variable, visit describes the impact of the first 6 months of TBP use, regardless of study arm.
Conflicts of interest: None disclosed.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Reprints not available from the authors. To the Editor: Urticaria can be associated with significant functional impairment. 1 While prevalence studies exist, few have explored the burden of urticaria worldwide, and to understand how a disease contributes to morbidity and mortality, measures beyond prevalence and incidence should be considered. The Global Burden of Disease (GBD) Study is a systematic, comprehensive effort to estimate the comparative magnitude of premature death and disability in [195 countries and 300 diseases. 2 To our knowledge, this study is the first effort to present GBD results regarding the burden of urticaria by age, sex, and geography.
Complete details of GBD methodology are available elsewhere. 3 Methods specific to the estimation of urticaria burden are presented here. A systematic review was performed on PubMed and Google Scholar to capture epidemiologic data for urticaria, including studies published during 1980-2014. Hospital outpatient and US claims data (using International Classification of Diseases, Tenth Revision, code L50) from 2000, 2010, and 2012 were also included. A Bayesian meta-regression tool, DisMod-MR 2.1, was used to model urticaria epidemiologic data points and estimate prevalence by age, sex, year, and country. Predictive covariates are used to create approximate estimates for countries lacking data. The GBD methods stratify disease-specific prevalence by severity level by assessing varying levels of itch, pain, and worry. Disability weights range from 0 (least disabling) to 1 (most disabling) and were derived from 4 population-based European surveys and an open-access web-based survey of 60,890 respondents. 3 Disease burden is measured by disability-adjusted life years (DALYs), combining morbidity ( years lost to disability) with mortality (life-years lost), such that 1 DALY is equivalent with 1 healthy lifeeyear lost. 3 The global age-standardized DALY rate for urticaria is 55.49/100,000 population. Among skin disease, the global burden from urticaria in 2016 ranks only behind acne vulgaris (214/100,000), dermatitis (152/100,000), viral skin disease (80.02/100,000) and psoriasis (76/100,000). 2 The 3 world regions with the greatest DALY rates for urticaria are Central Europe (61.8/100,000 population), Eastern Europe (60.7/100,000 population), and Central Asia (60.6/100,000 population). Fig 1 depicts the urticaria DALY rate per country. The age-standardized DALY rate for urticaria is 47.4/100,000 population and 62.5/100,000 population in male and female persons, respectively. Analysis of urticarial burden of disease by age group shows that children aged 1-4 years have the highest burden of disease (164.02/100,000 population), followed by postnatal infants (129.98/100,000 persons) and those aged 5-9 years (85.06/100,000 population). Fig 2 depicts the DALY rate for the consecutive age categories studied.
Limitations of the GBD Studies have been previously described. 4 Although the GBD model relies on high-quality analysis and statistics, it is not a perfect prediction model, and the data do not differentiate between chronic and acute episodes of urticaria. Despite the limitations, the GBD data offer a solid base for further studies to build upon. Targeted therapy (anti-IgE) for urticaria has a potential to decreased overall morbidity associated with the disease. 5 The data presented in this study highlight the variation in burden of disease by geography, sex, and age, which can be used to guide further research on targeted therapies, especially for populations heavily affected by urticaria. 
